相关实验视频

Updated: Jun 11, 2026

Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection

Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection

Published on: July 25, 2017

在常规实践中对卵巢癌的HRD测试:我们正在处理什么?

Tatiana Kekeeva¹, Yulia Andreeva², Alexander Tanas¹

¹Laboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie St., 1, 115522 Moscow, Russia.

International journal of molecular sciences

|July 14, 2023

概括

在卵巢癌中,使用AmoyDx试验可以进行同源重组缺陷 (HRD) 测试. 诸如瘤纯度和化疗反应等因素影响HRD得分,对患者管理至关重要.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
临床诊断临床诊断临床诊断

背景情况:

对同源重组缺陷 (HRD) 的评估对于管理卵巢癌患者至关重要.
艾莫伊HRD焦点测试为HRD测试提供了一个潜在的方法.

研究的目的:

评估Amoy HRD焦点测试在常规临床实践中的可行性.
分析种族差异,瘤纯度和新辅助化疗对HRD得分的影响.

主要方法:

在452个卵巢癌样本中分析HRD状态 (BRCA状态,基因组痕得分).
使用Amoy HRD焦点面板进行测试.

主要成果:

人力资源开发者测试成功率为86%.
BRCA突变率为29%,其中65%的样本被归类为HRD阳性.
俄罗斯人口的人力资源发展率与欧洲人口相似.
化疗反应 (1-2级) 和瘤纯度 (≥40%) 显著影响HRD得分.

结论:

AmoyDx HRD焦点小组是可行的HRD测试在高度血清性卵巢癌.
瘤纯度和化疗反应是影响HRD得分的关键因素.

关键词:

这是一种BRCA突变.基因组不稳定性得分同类重组缺陷的同类重组缺陷病理反应是一种病理反应.瘤的纯度瘤的纯度

更多相关视频

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

相关概念视频

Oogenesis

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...